4 January 2019
Peter Hamer joins SurgaColl as Chief Executive Officer
Alderley Park, UK – 10th December 2018. SurgaColl, a regenerative medicine company, today announced the appointment of Peter Hamer as Chief Executive Officer. Mr. Hamer succeeds Bill Allan as CEO following Bill’s decision to retire from full time executive roles. Peter has held multiple leadership positions in the MedTech/Medical Devices sector and has been responsible for product development, marketing and international sales & distribution in the fields of sports medicine, regenerative medicine and orthopaedics. He worked with Biomet for almost 20 years in a number of senior roles, including Vice President Sports Medicine EMEA and with the Corin Group as International Sales Director. More recently, in the field of regenerative medicine he served as Global Commercial Director, Orthopaedics with Tissue Regenix.
Mr Pat Forristal, Chairman of SurgaColl, said “We are very pleased to welcome Peter to the SurgaColl team and we look forward to leveraging his significant industry expertise, leadership experience and track record as we build the clinical evidence for our exciting regenerative products and prepare the company to take advantage of the global market opportunities ahead. We would also like to thank Bill Allan for the leadership he has provided to the SurgaColl business over the past two years in positioning our clinical, regulatory and operational strategies for future success. Bill will continue to serve on the company’s board of directors.”
SurgaColl is an innovative medical device company supplying novel tissue regeneration products for the surgical treatment of disease of the bone, cartilage and other human tissue. The company’s products are based on technologies developed by the Tissue Engineering Research Group (TERG) at the Royal College of Surgeons in Ireland (RSCI), headed by Professor Fergal O’Brien. The company’s mission is to become a technology development leader in the field of Regenerative Medical Devices.
SurgaColl’s headquarters is at Alderley Park, Cheshire, the UK’s largest bioscience campus, and its development centre is at the Dublin City University (DCU) campus in Ireland.